October 27th, 2010
A new drug is showing remarkable promise in treating lung cancer patients who have a rare genetic mutation. The drug, crizotinib, stabilized or improved the disease in 90 percent of patients in an early stage clinical trial, according to study results released Wednesday in the New England Journal of Medicine (NEJM).
“Some of our patients will notice improvement of their symptoms within a few days or a week,” said Dr. Alice Shaw, one of the drug’s lead investigators. “These responses are dramatic.”
October 27th, 2010
What a night! Roughly 80 friends and family members gathered at Wine Styles in Marysville tonight to taste wine for a lung cancer fundraiser. The Schmitt family would like to thank everyone who participated in the event, donated to our fundraising efforts or sent well wishes. Our event was a huge success having raised $2,230 for the Bonnie J. Addario Lung Cancer Foundation.
October 27th, 2010
Blog about VAP Prevention “Best Practices” success stories
Search for and share product and procedure video demonstrations
Engage in on-going debates about the latest regulatory issues impacting your practice
Posting questions about clinically- accredited education courses
October 18th, 2010
Like most patients with lung cancer, college student Jill Costello was well aware of the disparity in research funding and sympathy, and she set out to make a difference to advocate for others with lung cancer. In one short year, she inspired a nation of her peers – thousands of college students from Berkeley to Harvard to Northeastern to Yale who have rallied to raise funds and put an end to this #1 cancer killer.
October 15th, 2010
Wouldn’t it be wonderful if your every day debit/credit card purchases could also help raise funds for Lung Cancer research? Well, guess what? Today that capability is here, and with your help, the Bonnie J. Addario Lung Cancer Foundation (BJALCF) has a chance to receive a $10,000 donation from BBVA Compass through its Compass for Your Cause program. This is a tremendous opportunity! Apply Online Today.
PLEASE read the instructions FIRST and when you sign up, PLEASE be sure to include our code 84799 at the end of the application process where it asks for “Compass for a Cause” code, or we will not get credited.
October 13th, 2010
Jennifer Windrum, founder of the “WTF?” (Where’s the Funding) for Lung Cancer? campaign announces winners of the “WTF?”and the Bonnie J Addario Lung Cancer Foundation “ANYONE Can Get Lung Cancer” contest. The social media contest lasted three weeks and raised 50. All funds go to the Bonnie J Addario Lung Cancer Foundation. Prizes donated included an all-expenses paid golf package at Wild Horse Golf Course, Targus Laptop Backpacks and Jessica Kagan Cushman bangles.
October 11th, 2010
Thanks to all who came out on Sunday morning in Atlanta!
October 7th, 2010
Early detection is critical for improving cancer survival rates. Yet, one of the deadliest cancers in the United States,
lung cancer, is notoriously difficult to detect in its early stages.
Now, researchers have developed a method to detect lung cancer by merely shining diffuse light on cells swabbed from patients’ cheeks.
In a new clinical study, the analysis technique—called partial wave spectroscopic (PWS) microscopy—was able to differentiate individuals with lung cancer from those without, even if the non-cancerous patients had been lifetime smokers or suffered from chronic obstructive pulmonary disease (COPD).
The findings released by a team of engineers and physicians from NorthShore University Health System, Northwestern University and New York University appear in print in the Oct. 15, 2010, issue of the journal Cancer Research.
October 6th, 2010
- Explain to patients that a targeted therapy resulted in better outcomes than chemotherapy for selected patients with nonsmall-cell lung cancer.
- The subset of patients who benefited from the targeted agent account for a minority of the entire population of patients with NSCLC.
Targeted therapy with gefitinib (Iressa) led to a fourfold improvement in progression-free survival, compared with chemotherapy in selected patients with nonsmall-cell lung cancer (NSCLC), a multinational group of Asian investigators reported.
The 12-month progression-free survival was 24.9% with the inhibitor of epidermal growth factor receptor (EGFR),versus 6.7% with carboplatin-paclitaxel chemotherapy. The best results occurred in patients with mutated EGFR.
The trial was limited to nonsmokers and former light smokers (defined as <10 pack-years) with advanced pulmonary adenocarcinoma, according to an article published online in the New England Journal of Medicine.
“This study shows that first-line therapy with gefitinib as compared with carboplatin-paclitaxel prolongs progression-free survival, increases the objective response rate, and improves quality of life among clinically selected patients with nonsmall-cell lung cancer,” Tony S. Mok, MD, of the Chinese University of Hong Kong, and colleagues concluded.
